YMAB Y-mAbs Therapeutics, Inc.

3d ago, source: Seeking Alpha

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the ...

Buy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy Platform

2d ago, source: Business Insider

Begin your TipRanks Premium journey today. Y-Mabs Therapeutics (YMAB) Company Description: Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody ...

Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates

3d ago, source: Yahoo Finance

Warning! GuruFocus has detected 4 Warning Sign with YMAB. On May 7, 2024, Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a leader ...

Y-mAbs Therapeutics, Inc.

4mon ago, source: CNN

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer.

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

3d ago, source: Business Insider

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Y-mAbs Therapeutics Inc

22d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Y-mAbs Therapeutics Inc.

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...